• Armata Pharmaceuticals secured two newly issued U.S. patents covering bacteriophage candidates AP-SA02, AP-PA02.
• Patents extend expected U.S. protection to at least February 2041 for AP-SA02, about January 2043 for AP-PA02.
• AP-SA02 targets adjunct treatment of complicated Staphylococcus aureus bacteremia, including MSSA, MRSA; Phase 3-ready superiority study planned later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA65609) on October 07, 2026, and is solely responsible for the information contained therein.